{"id":1117,"date":"2012-05-01T12:05:00","date_gmt":"2012-05-01T10:05:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2012\/direkte-nicht-durch-dihydrotestosteron-vermittelte-effekte-von-testosteron"},"modified":"2012-05-01T12:05:00","modified_gmt":"2012-05-01T10:05:00","slug":"direkte-nicht-durch-dihydrotestosteron-vermittelte-effekte-von-testosteron","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2012\/direkte-nicht-durch-dihydrotestosteron-vermittelte-effekte-von-testosteron","title":{"rendered":"Direkte, nicht durch Dihydrotestosteron vermittelte Effekte von Testosteron"},"content":{"rendered":"<p>Ein Teil der zahlreichen Effekte von Testosteron (T), die \u00fcber den Androgen-Rezeptor (AR) vermittelt werden, erfolgt direkt, indem T an den intrazellul\u00e4ren AR bindet und im Zellkern zur Transaktivierung bestimmter Gene f\u00fchrt. In der Prostata, in der Genitalregion und in Hautanhangsgebilden wird T jedoch durch die hochaktiven 5-alpha-Reduktasen Typ 1 und 2 (5-AR) intrazellul\u00e4r zu [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ein Teil der zahlreichen Effekte von Testosteron (T), die \u00fcber den Androgen-Rezeptor (AR) vermittelt werden, erfolgt direkt, indem T an den intrazellul\u00e4ren AR bindet und im Zellkern zur Transaktivierung bestimmter Gene f\u00fchrt. In der Prostata, in der Genitalregion und in Hautanhangsgebilden wird T jedoch durch die hochaktiven 5-alpha-Reduktasen Typ 1 und 2 (5-AR) intrazellul\u00e4r zu [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[2781,2782,1474,1090,567],"class_list":["post-1117","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-dihydrotestosteron","tag-dutasterid","tag-finasterid","tag-prostatahyperplasie","tag-testosteron"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1117","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1117"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1117\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1117"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1117"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1117"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}